- Company
- The Paradox of Shingrix
- by Moon, sung-ho Feb 14, 2023 05:48am
- Domestic companies such as GC Pharma are in trouble. Shingrix Expected to Change the Domestic Shingles Vaccine Market With Expensive Premium Vaccine. Analysts say that two months after its launch in Korea, it is rarely showing its strength in the hospital and clinic markets. In particular, at the clinical site, GlaxoSmithKline (GSK) seems to
- Company
- “5 of 10 TNF-αis prescribed last year were adalimumab”
- by Kim, Jin-Gu Feb 14, 2023 05:48am
- On the 13th, the healthcare big data analysis service Evidnet released the results of its analysis on the prescription data of 10 general hospitals nationwide last year. According to the results, ‘adalimumab (Humira)’ was the most frequently prescribed TNF- α inhibitor last year. Evidnet analyzed and announced 18,371 prescription data on
- Company
- Forxiga's patent war ended after eight years
- by Kim, Jin-Gu Feb 13, 2023 05:59am
- The Supreme Court sided with Generic in the dispute over Forxiga patents for SGLT-2 inhibitor-based diabetes treatment. Patent challengers will be able to release generics early after April 7. The Supreme Court's special second division ruled in the morning of the 2nd that AstraZeneca would dismiss the appeal in an appeal filed against 17 com
- Company
- Daewoong Nabota has obtained an item license in Singapore
- by Kim, Jin-Gu Feb 13, 2023 05:59am
- Daewoong Pharmaceutical announced on the 9th that its botulinum toxin "Nabota" obtained an item license in Singapore on the 20th of last month. The acquisition of Singapore permits was the first of its kind among domestic botulinum drugs, and Nabota has increased the number of licensed countries worldwide to 62. Nabota 100 units are approv
- Company
- Generic for Dukarb is coming soon
- by Kim, Jin-Gu Feb 13, 2023 05:58am
- According to the second trial decision of Dukarb on the 16th of this month, it is decided whether to release the core capacity at the same time. With Boryung Kanarb's generic set to be released next month, attention is focused on the second trial of the patent dispute, which is three days away. This is because the decision of the patent c
- Company
- GC Pharma reinforces sales partnerships
- by Kim, Jin-Gu Feb 13, 2023 05:58am
- GC Pharma has been strengthening partnerships with pharmaceutical and biohealth companies in Korea and abroad by signing a series of copromotion agreements. After the company signed a copromotion agreement for GSK’s shingles vaccine ‘Shingrix’ at the end of last year, the company recently also signed an agreement to copromote Sanofi
- Company
- Can Jakavi be reimbursed for GvHD within the year?
- by Eo, Yun-Ho Feb 13, 2023 05:58am
- Whether reimbursement of ‘Jakavi’ be extended to cover Graft versus Host Disease (GvHD) is gaining attention. Novartis Korea submitted an application to extend reimbursement of its Jakavi (ruxolitinib) to GvHD immediately after receiving approval for the indication in May 2022. However, 8 months have passed and no progress has been m
- Company
- One step left to Dupixent’s reimb in pediatric patients
- by Eo, Yun-Ho Feb 10, 2023 05:53am
- The atopic dermatitis treatment ‘Dupixent’ has entered the last phase of extending its reimbursement coverage to children and adolescents. According to industry sources, Sanofi-Aventis Korea is conducting drug pricing negotiations for the low-dose formulation (200mg) of Dupixent (dupilumbab) with the National Health Insurance Service. T
- Company
- Botulinum Xeomin can be stored at room temperature
- by Jung, Sae-Im Feb 10, 2023 05:52am
- "Improving toxin quality and strengthening management change perceptions Merz's botulinum toxin Xeomin has been upgraded to room-temperature storage. It emphasized quality as the only room-temperature storage product with the highest purity among botulinum toxin drugs on the market in Korea. Merz held a press conference at the Grand InterCon
- Company
- 80 billion won worth of Anticonvulsant Market
- by Nho, Byung Chul Feb 9, 2023 05:49am
- In the 80 billion Anticonvulsant market, Topiramate-based treatments form 30 billion units, leading the market. The epilepsy drug consists of about 10 components, including Topiramate, Lamotrigine, sodium Valproate, Oxcarbazepine, and Perampanel. According to the drug distribution performance data, as of last year, the performance of Lamotrig
